Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antithymocyte immunoglobulin rabbit
- Development stage
- Approved
- Lead developer
- Charité Universitätsmedizin Berlin
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Antithymocyte immunoglobulin rabbit** is a rabbit-derived polyclonal immunoglobulin G preparation produced by immunizing rabbits with human thymocytes. It contains cytotoxic antibodies against multiple T-lymphocyte surface antigens and produces broad T-cell depletion and immunosuppression through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, apoptosis, and modulation of T-cell activation and trafficking. Marketed as **Thymoglobulin**, it is approved for prophylaxis and treatment of acute kidney-transplant rejection when used with concomitant immunosuppression. It is supplied as a lyophilized powder for intravenous infusion and is also used in transplant-conditioning and graft-versus-host disease prevention protocols. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbd8ab99-552e-4b81-aca4-6b0c7af8b9ae))
- Brand names
- ThymoglobulinThymoglobuline
- Other names
- anti-human thymocyte immunoglobulin rabbitanti-thymocyte globulin rabbitantithymocyte globulin rabbitrabbit anti-thymocyte globulinrATG
02
Targets
ITGAL (Integrin alpha L (CD11a))ITGB2 (Complement receptor 4)CD19 (B lymphocyte antigen CD19)CD2 (T-cell Surface Antigen CD2)CD20 (B-lymphocyte antigen CD20)IL2RA (Interleukin-2 receptor alpha subunit)CD3 (T-cell surface glycoprotein CD3)CD4 (T lymphocyte surface antigen)CD44 (CD44 antigen)CD8A (CD8 alpha/beta Coreceptor)CXCR4 (C-X-C motif chemokine receptor 4)HLA class I heavy chainHLA-DR (Human leukocyte antigen DR)CD45RA (T-cell surface glycoprotein CD45 isoform RA)
Beyond the preview
Go deeper on antithymocyte immunoglobulin rabbit.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antithymocyte immunoglobulin rabbit.